Clinical Trial

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with primary immune thrombocytopenia (ITP). The main questions it aims to answer are: * Is PN20 safe in these patients? * Could these patients potentially benefit from PN20 treatment? Participants will * Receive one subcutaneous injection of PN20 according to weight; * Visit the clinic for assessment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-11.
Trial Details
NCT Number NCT06880081
Lead Sponsor Chongqing Peg-Bio Biopharm Co., Ltd.
Conditions Primary Immune Thrombocytopenia (ITP)
Enrollment 12 participants
Start Date 2025-03-07
Primary Completion 2026-02-27 (estimated)
Study Completion 2026-04-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-02